Abstract 769P
Background
Pharmacokinetic (PK) boosting is the intentional use of a drug-drug interaction to enhance systemic drug exposure. PK boosting of olaparib, a CYP3A-substrate, has the potential to reduce PK variability and financial expenses. The aim of this study was to investigate equivalence of a boosted, reduced dose of olaparib compared to the non-boosted standard dose.
Methods
This randomized, cross-over, multicenter trial compared the PK of olaparib 300 mg twice daily (BID) followed by olaparib 100 mg BID boosted with the non-therapeutic CYP3A-inhibitor cobicistat 150 mg BID for 7 days, or vice versa, in patients treated with olaparib. Equivalence was defined as a geometric mean ratio (GMR) of area-under-the-curve over one dosing interval (AUC0-12h) and 90% Confidence Interval (CI) within the no-effect boundaries of 0.57-1.25.
Results
Of 15 included patients, 12 were eligible for PK analysis. The AUC0-12h increased with the boosted reduced dose with a GMR of 1.45 (90% CI 1.27-1.65). The maximum plasma concentration was comparable (GMR 0.97; 90%CI 0.84-1.12), and the trough plasma concentration increased (GMR 4.14; 90%CI 3.25-5.27). PK parameters of both therapies are shown in the table. No grade ≥3 adverse events were reported during the study. Table: 769P
Pharmacokinetic parameters of the standard monotherapy and boosted therapy of olaparib. Data are represented as geometric mean (CV%) [confidence interval]
Monotherapy [95%CI] | Boosted therapy [95%CI] | Geometric mean ratio [90%CI] | |
AUC 0-12h (mg*h/L) | 29.4 (46%) [22.2 – 38.9] | 42.7 (41%) [33.2 – 55.1] | 1.45 [1.27 – 1.65] |
C max (mg/L) | 6.37 (37%) [5.07 – 8.00] | 6.19 (28%) [5.19 – 7.39] | 0.97 [0.84 – 1.12] |
T max (h) | 1.25 (66%) [0.85 - 1.83] | 1.67 (42%) [1.30 – 2.16] | 1.34 [1.03 – 1.75] |
C trough (mg/L) | 0.39 (107%) [0.21 – 0.73] | 1.56 (77%) [0.99 – 2.46) | 4.14 [3.25 – 5.27] |
Conclusions
Boosting a 100 mg olaparib dose with the strong CYP3A-inhibitor cobicistat increases olaparib exposure with 45%, compared to the standard dose of 300 mg. Boosting of olaparib is therefore a promising strategy to reduce the olaparib dose. These results encourage a prospective study of boosted olaparib with toxicity-guided dose reductions. If adequate tolerability is established, boosting can lead to a substantial reduction in olaparib therapy costs. Drs. N.A.D. Guchelaar and M.I. Mohmaed Ali have equally contributed to the study.
Clinical trial identification
NCT05078671.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
ZonMw , The Netherlands Organization for Health Research and Development, as part of the Goed Gebruik Geneesmiddelen program (grant 10140021910005).
Disclosure
R.H. Mathijssen: Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer-Ingelheim, Novartis; Financial Interests, Institutional, Coordinating PI: Pamgene. I. Boere: Financial Interests, Institutional, Research Funding: GSK. P. Hamberg: Financial Interests, Personal, Advisory Board: Astellas, MSD, Pfizer, AstraZeneca, BMS, Ipsen. G.S. Sonke: Financial Interests, Research Funding: Merck, Agendia, AstraZeneca, Roche, Novartis; Financial Interests, Speaker, Consultant, Advisor: Novartis, Seattle Genetics, Biovica. N.P. Van Erp: Financial Interests, Institutional, Invited Speaker: Wad'n Workshop; Financial Interests, Institutional, Coordinating PI, IDS: Ipsen, Astellas. All other authors have declared no conflicts of interest.
Resources from the same session
768P - Preliminary results of an open-label, multicentric, phase Ib/II study to assess the safety and efficacy of AsiDNA, a DNA repair inhibitor, in addition to PARP inhibitor in patients with relapsed platinum sensitive ovarian cancer already treated with PARPi for at least 6 months (RevoCAN)
Presenter: Patricia Pautier
Session: Poster session 11
770P - Tolerability and efficacy of trabectedin plus pegylated liposomal doxorubicin (PLD) in elderly patients with ovarian cancer (OC): GEICO 105-O study
Presenter: Maria Jesus Rubio Perez
Session: Poster session 11
771P - Genomic characterization of advanced endometrial carcinosarcoma: Identification of potentially actionable targets
Presenter: Ugo De Giorgi
Session: Poster session 11
773P - Real-world results of homologous recombination deficiency testing: Comparison between two methods on 2,655 ovarian cancer patients in Spain
Presenter: Conxi Lazaro
Session: Poster session 11
774P - CCNE1 amplification defines a good prognostic subgroup among BRCAwt/HRDneg advanced high-grade ovarian cancer (HGOC)
Presenter: Felix Blanc-Durand
Session: Poster session 11
775P - A gene expression signature to predict benefit from intraperitoneal (IP) carboplatin chemotherapy in ovarian carcinoma (OC): Translational research study from the intraperitoneal therapy for ovarian cancer with carboplatin (iPocc) phase II/III trial
Presenter: David SP Tan
Session: Poster session 11
776P - Multi-omics analysis of chemo-refractory high-grade serous carcinoma patients: Insights from the DECIDER study
Presenter: Daria Afenteva
Session: Poster session 11
777P - Targeting cadherin-6 in epithelial ovarian cancer: Clinical significance of its expression and efficacy of raludotatug deruxtecan (R-DXd) in patient-derived cell models
Presenter: Daisuke Shintani
Session: Poster session 11
778P - Combined targeting poly (ADP-ribose) polymerase and receptor tyrosine kinase inhibits ovarian clear cell carcinoma progression via disrupted ribosomal biogenesis
Presenter: Chyong-Huey Lai
Session: Poster session 11
779P - Assessment of the RAD51 test to determine homologous recombination deficiency (HRD) in patients (pts) with newly diagnosed advanced high-grade epithelial ovarian cancer carcinoma (HGOC)
Presenter: Carmen Garcia Duran
Session: Poster session 11